JP2025060686A5 - - Google Patents
Info
- Publication number
- JP2025060686A5 JP2025060686A5 JP2024218275A JP2024218275A JP2025060686A5 JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5 JP 2024218275 A JP2024218275 A JP 2024218275A JP 2024218275 A JP2024218275 A JP 2024218275A JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- atrasentan
- human subject
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026010769A JP2026090302A (ja) | 2019-12-17 | 2026-01-26 | アトラセンタンによるiga腎症を治療する方法 |
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949115P | 2019-12-17 | 2019-12-17 | |
| US62/949,115 | 2019-12-17 | ||
| US202063005003P | 2020-04-03 | 2020-04-03 | |
| US63/005,003 | 2020-04-03 | ||
| US202063072699P | 2020-08-31 | 2020-08-31 | |
| US63/072,699 | 2020-08-31 | ||
| US202063084739P | 2020-09-29 | 2020-09-29 | |
| US63/084,739 | 2020-09-29 | ||
| US202063125205P | 2020-12-14 | 2020-12-14 | |
| US63/125,205 | 2020-12-14 | ||
| JP2022537007A JP7624995B2 (ja) | 2019-12-17 | 2020-12-16 | アトラセンタンによるiga腎症を治療する方法 |
| PCT/US2020/065311 WO2021126977A1 (en) | 2019-12-17 | 2020-12-16 | Methods of treating iga nephropathy with atrasentan |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537007A Division JP7624995B2 (ja) | 2019-12-17 | 2020-12-16 | アトラセンタンによるiga腎症を治療する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026010769A Division JP2026090302A (ja) | 2019-12-17 | 2026-01-26 | アトラセンタンによるiga腎症を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025060686A JP2025060686A (ja) | 2025-04-10 |
| JP2025060686A5 true JP2025060686A5 (cg-RX-API-DMAC7.html) | 2025-10-27 |
| JP7821870B2 JP7821870B2 (ja) | 2026-02-27 |
Family
ID=76478538
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537007A Active JP7624995B2 (ja) | 2019-12-17 | 2020-12-16 | アトラセンタンによるiga腎症を治療する方法 |
| JP2024218275A Active JP7821870B2 (ja) | 2019-12-17 | 2024-12-12 | アトラセンタンによるiga腎症を治療する方法 |
| JP2026010769A Pending JP2026090302A (ja) | 2019-12-17 | 2026-01-26 | アトラセンタンによるiga腎症を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537007A Active JP7624995B2 (ja) | 2019-12-17 | 2020-12-16 | アトラセンタンによるiga腎症を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026010769A Pending JP2026090302A (ja) | 2019-12-17 | 2026-01-26 | アトラセンタンによるiga腎症を治療する方法 |
Country Status (21)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20260121T1 (hr) | 2019-12-17 | 2026-03-13 | Chinook Therapeutics, Inc. | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije |
| CN114910647A (zh) * | 2022-05-07 | 2022-08-16 | 浙江大学 | 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用 |
| WO2023220930A1 (en) * | 2022-05-17 | 2023-11-23 | Increvet, Inc. | Veterinary pharmaceutical formulations cross-references to related applications |
| JP2025517355A (ja) * | 2022-05-19 | 2025-06-05 | チヌーク セラピューティクス,インコーポレイテッド | アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法 |
| WO2024073672A1 (en) | 2022-09-30 | 2024-04-04 | Travere Therapeutics, Inc. | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders |
| US20260130933A1 (en) * | 2022-10-05 | 2026-05-14 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin |
| AU2023366516A1 (en) * | 2022-10-28 | 2025-05-15 | Aduro Biotech Holdings, Europe B.V. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| WO2024099272A1 (zh) * | 2022-11-07 | 2024-05-16 | 信瑞诺医药(上海)有限公司 | 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合 |
| TW202604476A (zh) * | 2024-06-21 | 2026-02-01 | 大陸商深圳信立泰藥業股份有限公司 | 內皮素a(eta)受體拮抗劑聯用sglt-2抑制劑的醫藥用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5236940A (en) | 1988-12-15 | 1993-08-17 | Rhone-Poulenc Sante | Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US20020062121A1 (en) | 1995-05-16 | 2002-05-23 | Karl Tryggvason | Perfusion apparatus and methods for pharmaceutical delivery |
| ES2259803T3 (es) | 1996-02-13 | 2006-10-16 | Abbott Laboratories | Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina. |
| US20040191774A1 (en) | 2001-09-11 | 2004-09-30 | Moskowitz David W | Endothelin-1 promoter polymorphism |
| AU2003221042A1 (en) | 2002-03-22 | 2003-10-08 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic agent for kidney disease |
| US20070134247A9 (en) | 2002-04-12 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| US20030229906A1 (en) | 2002-04-15 | 2003-12-11 | Gelman Irwin H. | Methods and compositions for the treatment of disorders of HIV infection |
| US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| WO2006034084A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| WO2006034085A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form of atrasentan hydrochloride |
| US20060189675A1 (en) | 2004-09-17 | 2006-08-24 | Steve King | Crystalline form of a drug |
| WO2007109244A2 (en) | 2006-03-21 | 2007-09-27 | Morehouse School Of Medicine | Novel nanoparticles for delivery of active agents |
| KR20080108570A (ko) * | 2006-03-27 | 2008-12-15 | 제넨테크, 인크. | 신장 질환을 치료하는 방법 |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| ZA200902814B (en) | 2007-01-16 | 2010-08-25 | Musc Found For Res Dev | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
| CN101801936B (zh) | 2007-07-31 | 2012-10-03 | 吉利德科罗拉多公司 | 安立生坦的代谢物和衍生物 |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| US20120083421A1 (en) | 2008-10-16 | 2012-04-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan) |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2011070049A1 (en) | 2009-12-09 | 2011-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
| US9255931B2 (en) | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| CN103025670B (zh) | 2010-07-28 | 2016-08-10 | 日本电气硝子株式会社 | 荧光体封入用毛细管的制造方法、荧光体封入用毛细管、波长变换部件和波长变换部件的制造方法 |
| JP2016512201A (ja) * | 2013-03-08 | 2016-04-25 | アッヴィ・インコーポレイテッド | 急性腎障害の治療方法 |
| US9855245B2 (en) | 2013-04-30 | 2018-01-02 | Abbvie Inc. | Methods for improving lipid profiles using atrasentan |
| PE20160221A1 (es) | 2013-07-08 | 2016-05-22 | Abbvie Inc | Formas de dosificacion farmaceuticas estabilizadas que comprenden atrasentan |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
| WO2016073846A1 (en) * | 2014-11-07 | 2016-05-12 | Abbvie Inc. | Methods of treating ckd using predictors of fluid retention |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US20170014386A1 (en) | 2015-07-16 | 2017-01-19 | Abbvie, Inc. | Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children |
| IL300122A (en) * | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| CA3010593C (en) | 2016-01-05 | 2024-02-13 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| JP2019530713A (ja) * | 2016-10-13 | 2019-10-24 | レトロフィン, インコーポレイテッド | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| IL294410B2 (en) | 2016-11-23 | 2024-02-01 | Chemocentryx Inc | A method for the treatment of focal segmental tuberous sclerosis |
| MX386699B (es) | 2017-10-11 | 2025-03-19 | Chemocentryx Inc | Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2 |
| LT3716979T (lt) | 2017-11-30 | 2025-07-10 | Idorsia Pharmaceuticals Ltd | 4-pirimidinsulfamido darinio derinys su sglt-2 inhibitoriumi, skirtas su endotelinu susijusių ligų gydymui |
| US20220304979A1 (en) | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| HRP20260121T1 (hr) | 2019-12-17 | 2026-03-13 | Chinook Therapeutics, Inc. | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije |
| US20230270718A1 (en) | 2020-04-10 | 2023-08-31 | Chinook Therapeutics, Inc. | Methods of treating diabetic kidney disease |
| US20220243994A1 (en) | 2021-02-04 | 2022-08-04 | Northrop Grumman Systems Corporation | Metal woodpile capillary wick |
-
2020
- 2020-12-16 HR HRP20260121TT patent/HRP20260121T1/hr unknown
- 2020-12-16 WO PCT/US2020/065311 patent/WO2021126977A1/en not_active Ceased
- 2020-12-16 AU AU2020404984A patent/AU2020404984A1/en active Pending
- 2020-12-16 CA CA3161516A patent/CA3161516A1/en active Pending
- 2020-12-16 SI SI202030727T patent/SI4076652T1/sl unknown
- 2020-12-16 FI FIEP20903533.6T patent/FI4076652T3/fi active
- 2020-12-16 DK DK20903533.6T patent/DK4076652T3/da active
- 2020-12-16 RS RS20260142A patent/RS67746B1/sr unknown
- 2020-12-16 PL PL20903533.6T patent/PL4076652T3/pl unknown
- 2020-12-16 IL IL293921A patent/IL293921A/en unknown
- 2020-12-16 CN CN202310043260.6A patent/CN116327758A/zh active Pending
- 2020-12-16 KR KR1020227024511A patent/KR20230015874A/ko active Pending
- 2020-12-16 JP JP2022537007A patent/JP7624995B2/ja active Active
- 2020-12-16 EP EP20903533.6A patent/EP4076652B1/en active Active
- 2020-12-16 EP EP25219043.4A patent/EP4710928A3/en active Pending
- 2020-12-16 CN CN202080007568.XA patent/CN113272013A/zh active Pending
- 2020-12-16 MX MX2022007471A patent/MX2022007471A/es unknown
- 2020-12-16 TW TW114152252A patent/TW202615002A/zh unknown
- 2020-12-16 TW TW109144568A patent/TWI875895B/zh active
- 2020-12-16 PH PH1/2022/551456A patent/PH12022551456A1/en unknown
- 2020-12-16 PT PT209035336T patent/PT4076652T/pt unknown
- 2020-12-16 BR BR112022012075A patent/BR112022012075A2/pt unknown
- 2020-12-16 CN CN202310043259.3A patent/CN116173014A/zh active Pending
- 2020-12-16 TW TW114114616A patent/TWI914232B/zh active
- 2020-12-16 LT LTEPPCT/US2020/065311T patent/LT4076652T/lt unknown
-
2021
- 2021-06-30 US US17/363,604 patent/US20210353593A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/826,843 patent/US11491137B2/en active Active
- 2022-05-27 US US17/826,832 patent/US20220288026A1/en not_active Abandoned
- 2022-05-27 US US17/826,753 patent/US20220304978A1/en not_active Abandoned
- 2022-08-16 US US17/888,766 patent/US12582631B2/en active Active
-
2023
- 2023-07-18 US US18/223,355 patent/US12121509B2/en active Active
- 2023-07-18 US US18/223,340 patent/US11998526B2/en active Active
- 2023-07-18 US US18/223,290 patent/US20230355579A1/en not_active Abandoned
- 2023-11-29 US US18/523,609 patent/US12521369B2/en active Active
-
2024
- 2024-09-13 US US18/884,802 patent/US20250281454A1/en active Pending
- 2024-12-12 JP JP2024218275A patent/JP7821870B2/ja active Active
- 2024-12-20 US US18/990,351 patent/US12370174B2/en active Active
-
2026
- 2026-01-26 JP JP2026010769A patent/JP2026090302A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10206919B2 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| JP2024127897A5 (cg-RX-API-DMAC7.html) | ||
| RS66371B1 (sr) | Nova upotreba kombinacije blokera angiotenzinskih receptora (arb) sa neutralnim inhibitorom endopeptidaze (nepi) | |
| CN101420957B (zh) | 炎症性肠病治疗药 | |
| WO2007149283B1 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
| US20150320721A1 (en) | Combinations of sglt 2 inhibitors and antihypertensive drugs | |
| Dominguez Rieg et al. | New functions and roles of the Na+-H+-exchanger NHE3 | |
| WO2015129750A1 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| Fenier et al. | Enalapril improved renal function and proteinuria in chronic glomerulopathies | |
| Varda et al. | Diabetic kidney disease: from pathophysiology to treatment perspectives | |
| EP3090744A1 (en) | Pharmaceutical complex formulation comprising angiotensin ii receptor blocker and hmg-coa reductase inhibitor | |
| EP2837380A1 (en) | Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof | |
| JP7668386B2 (ja) | 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む薬学的組成物 | |
| US20110130421A1 (en) | Methods and Compositions for the Treatment of Chronic Renal Hypertension | |
| KR20230141662A (ko) | 높은 혈중 요산 농도를 갖는 대상체의 만성 신장 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 | |
| CN116887843A (zh) | 用于降低接受维持性透析的患者中的草酸盐/酯水平的组合物和方法 | |
| JPWO2011162390A1 (ja) | 徐放性高血圧および腎機能障害治療剤 | |
| CN100453081C (zh) | 用于治疗糖尿病性肾病的吡啶基亚磺酰氨基嘧啶 | |
| RU2741426C1 (ru) | Никотинамид для лечения дислипидемии | |
| US20150119401A1 (en) | Compositions and Methods for the Treatment of Nasal Conditions | |
| Ye et al. | Nonsteroidal anti-inflammatory drug use and acute kidney injury in nephrectomies: a retrospective propensity score-matched cohort study | |
| CN101014333A (zh) | 包含洛索洛芬的口服组合物 | |
| Sahai et al. | Pharmacology of the Therapeutic Approaches of Gout | |
| WO2022225044A1 (ja) | カリウム吸着薬を有効成分とする慢性腎不全(ckd)合併高カリウム血症患者の予後改善剤 | |
| Groothoff et al. | Long-Term Nedosiran Safety and Efficacy in Primary Hyperoxaluria Type 1 (PH1): Interim Analysis of PHYOX3: TH-PO1128 |